brigatinib — CareFirst (Caremark)

Initial criteria

• Diagnosis of symptomatic or relapsed/refractory ALK-positive Erdheim-Chester Disease (ECD)
• Used as a single agent

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months